Siponimod cuts risk of disability progression in multiple sclerosis

March 23, 2018

(HealthDay)—For patients with secondary progressive multiple sclerosis, the selective sphingosine 1-phosphate (S1P) receptor1,5 modulator, siponimod, is associated with reduced relative risk of confirmed disability progression, according to a study published online March 22 in The Lancet.

Ludwig Kappos, M.D., from the University of Basel in Switzerland, and colleagues conducted a phase 3 trial at 292 hospital clinics and specialized centers in 31 countries. Patients with SPMS and an Expanded Disability Status Scale score of 3.0 to 6.5 were randomized in a 2:1 ratio to once-daily oral siponimod 2 mg or placebo. A total of 1,645 patients were included in the analyses: 1,099 to the siponimod group and 546 to the ; 903 and 424 patients completed the study, respectively.

The researchers found that 26 and 32 percent of patients receiving siponimod and placebo had three-month confirmed disability progression events (hazard ratio, 0.79; relative risk reduction, 21 percent). Adverse events occurred in 89 and 82 percent of taking siponimod and placebo, respectively; serious were reported for 18 and 15 percent, respectively.

"Siponimod reduced the risk of disability progression with a safety profile similar to that of other S1P modulators and is likely to be a useful treatment for SPMS," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novartis, which manufactures siponimod and funded the study.

Explore further: Cannabidiol efficacious for lennox-gastaut drop seizures

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Cannabidiol efficacious for lennox-gastaut drop seizures

January 26, 2018
(HealthDay)—For patients with drop seizures associated with Lennox-Gastaut syndrome, add-on cannabidiol is associated with a reduction in monthly drop seizure frequency, according to a study published online Jan. 24 in ...

H. pylori treatment tied to lower metachronous gastric cancer risk

March 22, 2018
(HealthDay)—Antibiotic treatment for Helicobacter pylori (H. pylori) in patients who underwent endoscopic resection of early-stage gastric cancer or high-grade adenoma is associated with a reduced rate of metachronous gastric ...

Ulipristal achieves amenorrhea for symptomatic leiomyomas

February 20, 2018
(HealthDay)—For women with symptomatic uterine leiomyomas, ulipristal is well tolerated and superior to placebo for the rate of and time to amenorrhea, according to a study published online Feb. 5 in Obstetrics & Gynecology.

Dexamethasone no help in HIV-linked cryptococcal meningitis

February 12, 2016
(HealthDay)—For patients with HIV-associated cryptococcal meningitis, dexamethasone does not reduce mortality compared with placebo, according to a study published in the Feb. 11 issue of the New England Journal of Medicine.

Ixazomib ups progression-free survival in multiple myeloma

April 28, 2016
(HealthDay)—For patients with relapsed, refractory, or relapsed and refractory multiple myeloma, ixazomib is associated with prolonged progression-free-survival, according to a study published in the April 28 issue of the ...

Letermovir prophylaxis cuts risk of CMV infection

December 8, 2017
(HealthDay)—For cytomegalovirus (CMV)-seronegative patients undergoing hematopoietic-cell transplantation, letermovir prophylaxis is associated with a lower risk of CMV infection than placebo, according to a study published ...

Recommended for you

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

Researchers define possible molecular pathway for neurodegeneration in prion diseases

September 21, 2018
A new study has shed light on the mechanisms underlying the progression of prion diseases and identified a potential target for treatment.

Fighting a deadly parasite: Scientists devise a method to store Cryptosporidium, aiding vaccine research efforts

September 21, 2018
In May, just before one of the hottest summers on record, the U.S. Centers for Disease Control and Prevention issued a warning about diseases lurking in recreational water facilities like swimming pools and water playgrounds. ...

Scientists make significant discovery in the fight against drug-resistant tuberculosis

September 20, 2018
A team of scientists have identified a naturally occurring antibiotic that may help in the fight against drug-resistant Tuberculosis.

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.